138 related articles for article (PubMed ID: 975068)
1. Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells.
Papahadjopoulos D; Poste G; Vail WJ; Biedler JL
Cancer Res; 1976 Sep; 36(9 pt.1):2988-94. PubMed ID: 975068
[TBL] [Abstract][Full Text] [Related]
2. The relationship among transport, intracellular binding, and inhibition of RNA synthesis by actinomycin D in Ehrlich ascites tumor cells in vitro.
Bowen D; Goldman ID
Cancer Res; 1975 Nov; 35(11 Pt 1):3054-60. PubMed ID: 1182700
[TBL] [Abstract][Full Text] [Related]
3. Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.
Inaba M; Johnson RK
Cancer Res; 1977 Dec; 37(12):4629-34. PubMed ID: 922743
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential.
Lelièvre S; Larsen AK
Cancer Res; 1994 Aug; 54(15):3993-7. PubMed ID: 8033129
[TBL] [Abstract][Full Text] [Related]
5. Plasma membrane proteins and glycoproteins from Chinese hamster cells sensitive and resistant to actinomycin D.
Peterson RH; Biedler JL
J Supramol Struct; 1978; 9(3):289-98. PubMed ID: 748679
[TBL] [Abstract][Full Text] [Related]
6. Short exposure to actinomycin D induces "reversible" translocation of protein B23 as well as "reversible" inhibition of cell growth and RNA synthesis in HeLa cells.
Yung BY; Bor AM; Chan PK
Cancer Res; 1990 Sep; 50(18):5987-91. PubMed ID: 1697505
[TBL] [Abstract][Full Text] [Related]
7. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Meyers MB; Rittmann-Grauer L; O'Brien JP; Safa AR
Cancer Res; 1989 Jun; 49(12):3209-14. PubMed ID: 2566379
[TBL] [Abstract][Full Text] [Related]
8. Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line.
Melguizo C; Prados J; Fernández JE; Vélez C; Alvarez L; Aránega A
Cell Mol Biol (Noisy-le-grand); 1994 Mar; 40(2):137-45. PubMed ID: 7911694
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of vincristine and actinomycin D by a new synthetic imidazole anti-tumor agent YM534 active against human cancer cells and multidrug-resistant cells.
Sato S; Watanabe Y; Okamura K; Hamanaka R; Mori T; Kohno K; Kuwano M
Anticancer Drug Des; 1989 Aug; 4(2):125-35. PubMed ID: 2803461
[TBL] [Abstract][Full Text] [Related]
10. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
11. Sequential irreversible, actinomycin D-sensitive, and cycloheximide-sensitive steps prior to cortisol inhibition of uridine utilization by P1798 tumor lymphocytes.
Stevens J; Stevens YW
Cancer Res; 1975 Aug; 35(8):2145-53. PubMed ID: 1149029
[TBL] [Abstract][Full Text] [Related]
12. Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184.
Moy BC; Petzold GL; Badiner GJ; Kelly RC; Aristoff PA; Adams EG; Li LH; Bhuyan BK
Cancer Res; 1990 Apr; 50(8):2485-92. PubMed ID: 2317831
[TBL] [Abstract][Full Text] [Related]
13. Some biochemical properties of Chinese hamster cells sensitive and resistant to actinomycin D.
Peterson RH; O'Neil JA; Biedler JL
J Cell Biol; 1974 Dec; 63(3):773-9. PubMed ID: 4474176
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B-induced sensitivity to actinomycin D in drug-resistant Hela cells.
Medoff J; Medoff G; Goldstein MN; Schlessinger D; Kobayaski GS
Cancer Res; 1975 Sep; 35(9):2548-52. PubMed ID: 1149049
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by lipophilic drugs.
Hofsli E; Nissen-Meyer J
Cancer Res; 1990 Jul; 50(13):3997-4002. PubMed ID: 2354448
[TBL] [Abstract][Full Text] [Related]
16. [In vitro characterization of S9788, a new modulator of multidrug resistance].
Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
[TBL] [Abstract][Full Text] [Related]
17. [Cellular resistance to DNA-topoisomerase II inhibitors].
Jacquemin-Sablon A; Bojanowski K; Casabianca-Pignède MR; Crémier S; Delaporte C; Khelifa T; Markovits J; René B; Saucier JM; Larsen AK
Bull Cancer; 1994 May; 81(5):381-5. PubMed ID: 7749214
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the effects of lucanthone (miracil D) and actinomycin D on the Chinese hamster cells grown in cultures.
Epifanova OI; Makarova GF; Abuladze MK
J Cell Physiol; 1975 Oct; 86(2 Pt 1):261-8. PubMed ID: 1194365
[TBL] [Abstract][Full Text] [Related]
19. [Effect of actinomycin D on RNA synthesis in a stationary culture of Chinese hamster cells stimulated to proliferate].
Zosimovskaia AI; Terskikh VV
Tsitologiia; 1975 Jul; 17(7):791-6. PubMed ID: 1172310
[TBL] [Abstract][Full Text] [Related]
20. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft.
Rittmann-Grauer LS; Yong MA; Sanders V; Mackensen DG
Cancer Res; 1992 Apr; 52(7):1810-6. PubMed ID: 1348013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
